“No Major Findings”: The Hidden Risk

Welcome back to The Nonclinical, a newsletter where we unpack how nonclinical toxicology actually works inside drug development — beyond the protocol and into real decisions.

One of the most reassuring phrases in nonclinical development is also one of the most dangerous:

No major findings.

It appears in study reports, executive summaries, and program updates as a signal that risk has been cleared. In many cases, it’s used as shorthand for progress, permission to move forward, and confidence that the program is on track.

Sometimes, that confidence is earned. But often, “no major findings” doesn’t mean what teams think it means. It is a description of what was not observed. It is not an interpretation of what the study resolved.

That distinction matters more than most teams appreciate.

---

Early toxicology studies are rarely designed to produce binary outcomes. Their value isn’t just in whether a finding appears, but rather in the context they establish around exposure, dose-response, reversibility, and margin.

A clean study can still leave important questions open:

• How close was exposure to the intended clinical range?

• What assumptions are now being made about escalation?

• Which signals would become relevant under chronic dosing?

• What would actually change the program’s path if exposure increased?

“No major findings” doesn’t answer those questions. It often quiets them.

And once that phrase enters the conversation, behavior changes.

Attention shifts forward. Dose rationales harden. Exposure assumptions stop being tested and start being reused. Follow-on studies are designed from a position of reassurance rather than uncertainty. Confidence is at an all-time high, bordering on over-confidence.

Nothing looks wrong. But something important has been skipped.

Nonclinical studies may look good on paper, until you get to the justification part. 

The consequence of this gap usually doesn’t show up in nonclinical. It shows up later, when the program needs to explain itself. At IND or first-in-human stages, teams are no longer asked to summarize results. They’re asked to justify decisions:

Why was this starting dose considered appropriate? What evidence supports escalation beyond this exposure? How confident are you that this signal won’t reappear under longer dosing? What margin are you actually defending here?

These are not questions that can be answered retroactively with a clean report. They require interpretation that should have been articulated when the data were fresh and flexible.

By the time those questions surface, optionality is often gone. The program has already committed to a path. At that point, teams aren’t choosing the best answer, they’re defending the only one available.

This is where “no major findings” becomes a liability.

Not because it was wrong, but because it was treated as an endpoint instead of a transition.

Nonclinical summary results and the program-driven questions they draw out

Strong nonclinical programs treat clean studies as an opportunity to do more thinking, not less.

They use the absence of findings to define boundaries, document assumptions, and state explicitly:

• what risks are considered acceptable

• what signals would trigger reconsideration

• and what data would actually change the program’s direction

That work doesn’t feel urgent at the time. It doesn’t come with alarms or red flags. But it’s what determines whether a program moves smoothly into the clinic or spends months reconstructing decisions it thought were already made.

Without any major findings, there is no ceiling - or toxicological threshold - that has presented itself. There are no limits or boundaries for the molecule, the dose, the exposure or the toxicity. Without this, how can we sufficiently translate nonclinical to clinical? 

“No major findings” should never be the end of interpretation.

It should be the moment interpretation becomes explicit.

📍If you're building your tox career and want to understand how nonclinical development actually works, The Nonclinical is for you. Free. Every other Thursday. Subscribe below:

Dessi McEntee, MS, DABT is a board-certified toxicologist and the founder of Toxistrategy LLC. She works as a Fractional Head of Toxicology for early-stage biotechs navigating IND-enabling development — bringing senior nonclinical leadership to teams that need it without the cost of a full-time hire.

The Nonclinical is written for scientists, early-career toxicologists, and development teams who want to understand how nonclinical decisions actually get made — and why they matter.

Learn more at www.toxistrategy.com